Aprepitant a promising cough suppressant for advanced lung cancer patients
31 Jan 2020
byJairia Dela Cruz
A week-long course of the centrally acting neurokinin-1 inhibitor aprepitant for treating cough in advanced lung cancer patients is effective and safe, producing significant improvements in cough severity and impact without increasing severe side effects, according to the results of a trial.